Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta‐analysis

Published:2022-07-21 Issue:12 Volume:52 Page:
ISSN:0014-2972
Container-title:European Journal of Clinical Investigation
language:en
Short-container-title:Eur J Clin Investigation

Author:

Malaty Michael M.¹^ORCID,Amarasekera Anjalee Thanuja²³⁴,Li Cindy¹,Scherrer‐Crosbie Marielle⁵,Tan Timothy C.¹²³^ORCID

Affiliation:

1. Department of Cardiology, Blacktown Hospital Western Sydney Local Health District Sydney Australia

2. School of Medicine Western Sydney University Sydney Australia

3. Department of Cardiology, Westmead Hospital Western Sydney Local Health District Sydney Australia

4. Westmead Applied Research Centre (WARC), Faculty of Medicine and Health University of Sydney Sydney Australia

5. Division of Cardiovascular Diseases, Department of Medicine Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/eci.13831

Reference72 articles.

1. Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials

2. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials

3. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity

4. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure

5. Next generation of immune checkpoint inhibitors and beyond

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab and Cardiovascular Toxicity;JAMA;2024-04-16

2. Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure;Nature Reviews Cardiology;2024-01-26

3. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report;Frontiers in Immunology;2023-12-13

4. Immune Checkpoint Inhibitor-Mediated Cardiovascular Disease: The Dark Side of the Monoclonal Anti-Body Therapy against Cancer;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-09-07

5. Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring;European Heart Journal - Cardiovascular Imaging;2023-07-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3